Fulgent Genetics (STU:7F0) Cyclically Adjusted FCF per Share: €2.50 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7F0 Fulgent Genetics Inc STU:7F0
70 GF Score
Price €17.40
GF Value €21.18
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Fulgent Genetics Cyclically Adjusted FCF per Share?

Fulgent Genetics STU:7F0 +1.75% 70 Cyclically Adjusted FCF per Share is €2.50 as of Mar. 2026. GuruFocus rates STU:7F0 with a GF Score™ of 70/100 and a GF Value™ of €21.18 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Fulgent Genetics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.053. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €2.50 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Fulgent Genetics's average Cyclically Adjusted FCF Growth Rate was -10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-22), Fulgent Genetics's current stock price is €17.40. Fulgent Genetics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €2.50. Fulgent Genetics's Cyclically Adjusted Price-to-FCF of today is 6.96.

During the past 12 years, the highest Cyclically Adjusted Price-to-FCF of Fulgent Genetics was 9.89. The lowest was 4.87. And the median was 6.61.


Fulgent Genetics  (STU:7F0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Fulgent Genetics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=17.40/2.50
=6.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted Price-to-FCF of Fulgent Genetics was 9.89. The lowest was 4.87. And the median was 6.61.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Fulgent Genetics Cyclically Adjusted FCF per Share Related Terms


Fulgent Genetics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Fulgent Genetics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics Cyclically Adjusted FCF per Share Chart

Fulgent Genetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.42

Fulgent Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 2.57 2.60 2.42 2.50

STU:7F0 vs MYGN, CSTL, BDSX: Cyclically Adjusted FCF per Share Comparison

For the Diagnostics & Research subindustry, Fulgent Genetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics Cyclically Adjusted Price-to-FCF vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Cyclically Adjusted Price-to-FCF falls into.


STU:7F0
70GF Score
Fulgent Genetics Inc STU:7F0
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulgent Genetics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Fulgent Genetics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.053/330.2130*330.2130
=0.053

Current CPI (Mar. 2026) = 330.2130.

Fulgent Genetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.056 241.018 0.077
201609 -0.140 241.428 -0.191
201612 0.046 241.432 0.063
201703 0.073 243.801 0.099
201706 -0.043 244.955 -0.058
201709 -0.104 246.819 -0.139
201712 -0.113 246.524 -0.151
201803 -0.109 249.554 -0.144
201806 -0.029 251.989 -0.038
201809 -0.055 252.439 -0.072
201812 0.032 251.233 0.042
201903 0.045 254.202 0.058
201906 0.008 256.143 0.010
201909 0.178 256.759 0.229
201912 -0.026 256.974 -0.033
202003 0.024 258.115 0.031
202006 -0.187 257.797 -0.240
202009 -0.026 260.280 -0.033
202012 3.386 260.474 4.293
202103 6.052 264.877 7.545
202106 1.970 271.696 2.394
202109 4.058 274.310 4.885
202112 2.017 278.802 2.389
202203 5.320 287.504 6.110
202206 0.239 296.311 0.266
202209 0.502 296.808 0.558
202212 0.881 296.797 0.980
202303 -0.314 301.836 -0.344
202306 -0.075 305.109 -0.081
202309 0.166 307.789 0.178
202312 0.364 306.746 0.392
202403 0.099 312.332 0.105
202406 -0.267 314.175 -0.281
202409 -1.038 315.301 -1.087
202412 0.662 315.605 0.693
202503 -0.274 319.799 -0.283
202506 -1.050 322.561 -1.075
202509 0.140 324.800 0.142
202512 -2.291 324.054 -2.335
202603 0.053 330.213 0.053

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €2.50 mean?
Fulgent Genetics (STU:7F0) has a Cyclically Adjusted FCF per Share of €2.50 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Fulgent Genetics and its competitors.
Is Fulgent Genetics' Cyclically Adjusted FCF per Share too high?
Fulgent Genetics' current Cyclically Adjusted FCF per Share is €2.50. Overall, Fulgent Genetics has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Cyclically Adjusted FCF per Share compare to MYGN and CSTL?
Fulgent Genetics' Cyclically Adjusted FCF per Share of €2.50 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted FCF per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Cyclically Adjusted FCF per Share is €2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (STU:7F0) is currently considered Modestly Undervalued. The stock's GF Value™ is €21.18, compared to a current price of €17.40 — trading 17.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €2.50. Fulgent Genetics' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Fulgent Genetics (STU:7F0), the current Cyclically Adjusted FCF per Share is €2.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulgent Genetics (STU:7F0) Overvalued in 2026?

Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued. The current stock price of €17.40 is trading 17.8% below its estimated GF Value™ of €21.18. GuruFocus considers Fulgent Genetics to be Modestly Undervalued.

Key valuation signals for STU:7F0:

  • Cyclically Adjusted FCF per Share: €2.50
  • GF Value™: €21.18 vs. price of €17.40 (17.8% below fair value)
  • GF Score™: 70/100 with 4 warning signs

No single metric tells the full story. See the STU:7F0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fulgent Genetics Business Description

Other Exchanges FLGT:USAFLGT:Mexico
Address 4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
70GF Score

Get the complete analysis for STU:7F0

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.40
Price
€21.18
GF Value